INSPIRING: SAFETY AND EFFICACY OF DOLUTEGRAVIR-BASED ART IN TB/HIV COINFECTED ADULTS AT WEEK 24
|
|
- Godfrey Simmons
- 5 years ago
- Views:
Transcription
1 UK/DGR/14/18 Dte of prep: April 218 INSPIRING: SAFETY AND EFFICACY OF DOLUTEGRAVIR-BASED ART IN TB/HIV COINFECTED ADULTS AT WEEK 24 Dooley KE, 1 Kpln R, 2 Mwelse T, 3 Grinsztejn B, 4 Ticon E, 5 Lcerd M, 6 Chn P, 7 Belonosov E, 8 Ait-Khled M, 9 Angelis K, 1 Brown D, 11 Singh R, 12 Tlrico C, 13 Tenorio A, 13 Aboud M 9 1 Johns Hopkins University School of Medicine, Bltimore, MD, USA; 2 Desmond Tutu HIV Foundtion, Cpe Town, South Afric; 3 Clinicl HIV Reserch Unit, Johnnesburg, South Afric; 4 Instituto de Pesquis Clínic Evndro Chgs FIOCRUZ, Rio de Jneiro, Brzil; 5 Hospitl Dos de Myo, Lim, Peru; 6 Fiocruz/Tropicl Medicine Foundtion Dr Heitor, Vieir Dourdo, Mnus, Brzil; 7 Fundción Huésped, Bueno Aires, Argentin; 8 Regionl Center for Prevention nd Tretment of AIDS nd Infectious Diseses, Russi; 9 ViiV Helthcre, Brentford, UK; 1 GlxoSmithKline, Stockley Prk, UK; 11 ViiV Helthcre, Melbourne, Austrli; 12 ViiV Helthcre, Upper Merion, PA, USA; 13 ViiV Helthcre, Reserch Tringle Prk, NC, USA Conference on Retroviruses nd Opportunistic Infections; Mrch 4-7, 218; Boston, MA
2 Introduction Dolutegrvir (DTG)-bsed regimens re now recommended by WHO s lterntive first-line regimens; severl countries with high HIV prevlence hve dopted DTG-bsed regimens s first-line tretment Chrcterizing the efficcy, sfety, nd drug-drug interctions of DTG in ptients with tuberculosis (TB) co-infection is high priority Efvirenz (EFV) is commonly used, but lterntives to EFV re needed, prticulrly in the setting of dverse events nd trnsmitted drug resistnce to NNRTIs DTG hs some fetures tht my fvour its use: Good long term efficcy nd fvorble sfety profile High brrier to HIV-1 resistnce nd no impct of primry NNRTI resistnce (with prevlence ~1% in some regions) DTG hs low potentil for drug interctions nd is not n inducer of CYP45 enzymes In helthy volunteers, the ntituberculosis drug rifmpicin (RIF) reduced DTG C tu by 72% nd AUC -tu by 54% Decresed DTG plsm exposure is compensted for by incresing DTG dosge to 5 mg twice dily The INSPIRING study is being conducted to estimte the ntivirl efficcy nd evlute the sfety of DTG in ART-nive dults with HIV/TB coinfection Conference on Retroviruses nd Opportunistic Infections; Mrch 4-7, 218; Boston, MA Dooley et l. CROI 218; Boston, MA.
3 INSPIRING: Phse IIIb Study Design Phse IIIb, rndomized, multicenter, open-lbel, non-comprtive, ctive-control prllel-group study TB therpy HRZE (2 months) HR (4 months) DTG dose switch 2 weeks post-completion of TB tretment HIV/TB coinfected ART-nive dults DTG (5 mg BID) + 2 NRTIs (n = 69) EFV (6 mg QD) + 2 NRTIs (n = 44) DTG (5 mg QD) + 2 NRTIs Screening 28 to 14 dys Dy 1 Inclusion criteri HIV-1 RNA 1 copies/ml nd CD4+ 5 cells/mm 3 Pulmonry, pleurl, or lymph node tuberculosis with RIF-sensitive MTB confirmed by culture or GeneXpert RIF-contining TB tretment strted up to mximum of 8 weeks before rndomiztion nd no lter thn the screening dte 24 weeks Interim nlysis: % <5 c/ml (Snpshot) 52 weeks End of rndomized phse Primry endpoint t Week 48: % <5 c/ml (Snpshot) DTG:EFV 3:2 rndomiztion strtified by Screening plsm HIV-1 RNA 1, or >1, copies/ml Screening CD4+ 1 cells/mm 3 or >1 cells/mm 3 ART, ntiretrovirl therpy; DTG, dolutegrvir; EFV, efvirenz; HR, isonizid, rifmpin; HRZE, isonizid, rifmpin, pyrzinmide, ethmbutol; NRTI, nucleoside reverse trnscriptse inhibitor; RIF, rifmpin; TB, tuberculosis. Durtion of continution phse of TB tretment ccording to locl guidelines (continution phse up to 7 months in some countries). ClinTrils.gov NCT Conference on Retroviruses nd Opportunistic Infections; Mrch 4-7, 218; Boston, MA Dooley et l. CROI 218; Boston, MA.
4 Study Endpoints Primry Endpoint Proportion of DTG subjects with plsm HIV-1 RNA <5 c/ml t Week 48 using the modified Snpshot lgorithm in the ITT-E popultion Secondry Endpoints Proportion of subjects with plsm HIV-1 RNA <5 c/ml t Week 24 using the modified Snpshot lgorithm in the ITT-E popultion Proportion of EFV subjects with plsm HIV-1 RNA <5 c/ml t Week 48 using the modified Snpshot lgorithm in the ITT-E popultion Chnges from bseline in CD4+ counts t Week 24 nd Week 48 Incidence nd severity of ll AEs, SAEs, nd lbortory bnormlities Proportion of subjects with TB- nd non-tb-ssocited IRIS s ssessed by the IRIS independent djudiction pnel Incidence of tretment-emergent genotypic nd phenotypic resistnce to DTG, EFV, nd other on-study ART in subjects meeting confirmed virologic withdrwl criteri Modified snpshot: NRTI switch for tolerbility not counted s filure Conference on Retroviruses nd Opportunistic Infections; Mrch 4-7, 218; Boston, MA Dooley et l. CROI 218; Boston, MA.
5 INSPIRING Globl Enrollment (n=113) Totl number of sites: 37 First Subject First Visit: 23/1/215 Lst Subject First Visit: 13/1/217 Recruitment period: 21 months 1 SUBJECTS South-Afric Peru Brzil Mexico Russi Argentin Thilnd Prticipting Country Screened Rndomised Dooley et l. CROI 218; Boston, MA. Conference on Retroviruses nd Opportunistic Infections; Mrch 4-7, 218; Boston, MA
6 Demogrphic nd Bseline Chrcteristics Age, medin (min, mx), yers 5 yers, n (%) Prticipnts could hve hd pulmonry TB with pleurl or lymph node TB. DTG (n=69) 33 (18, 62) 9 (13) Conference on Retroviruses nd Opportunistic Infections; Mrch 4-7, 218; Boston, MA EFV (n=44) 32 (2, 5) 2 (5) Femle, n (%) 3 (43) 16 (36) Africn-Heritge/Africn, n (%) 47 (68) 29 (66) HIV-1 RNA, medin (Q1, Q3), log 1 copies/ml >1, copies/ml, n (%) CD4+ cell count, medin (Q1, Q3), cells/mm 3 1 cells/mm 3, n (%) 5.1 (4.74, 5.47) 44 (64) 28 (128, 41) 13 (19) 5.24 (4.5, 5.67) 24 (55) 22 (92, 354) 12 (27) CDC ctegory C, n (%) 69 (1) 44 (1) Current TB conditions, n (%) Pulmonry TB Lymph node TB Pleurl TB Time from strt of TB therpy to Dy 1, medin (Q1, Q3), dys Most common NRTI bckbone TDF/FTC TDF/3TC 65 (94) 5 (7) 5 (7) 44 (1) 1 (2) 35. (28., 44.) 33.5 (26., 52.) 47 (68) 4 (6) 31 (7) 3 (7) Dooley et l. CROI 218; Boston, MA.
7 Snpshot Outcomes t Week 24 Prticipnts, % DTG ITT-E (n=69) EFV ITT-E (n=44) DTG + 2 NRTIs n=69 n (%) EFV + 2 NRTIs n=44 n (%) Virologic Success (HIV-1 RNA <5 c/ml) 56 (81) 39 (89) Virologic nonresponse 7 (1) 3 (7) Dt in window not <5 c/ml 5 (7) 2 (5) Discontinued for other reson while not <5 c/ml 2 (3) 1 (2) Chnge in ART No virologic dt 6 (9) 2 (5) Discontinued due to AE or deth 1 (2) Discontinued for other resons 5 (7) 1 (2) Missing dt during window but on study 1 b (1) Virologic success Virologic nonresponse No virologic dt Discontinued for other resons: 4 lost to follow-up (dys 25, 8, 177, 181); 1 withdrwl of consent (dy 116). b <4 c/ml t Wk 12. Dooley et l. CROI 218; Boston, MA. Conference on Retroviruses nd Opportunistic Infections; Mrch 4-7, 218; Boston, MA
8 Confirmed Virologic Withdrwls Through Week 24 DTG n=69 EFV n=44 Confirmed virologic withdrwl (CVW), n (%) 1 (1) b Tretment-emergent resistnce-ssocited muttions NRTI n/ NNRTI n/ INSTI n/ Confirmed plsm HIV-1 RNA 4 copies/ml t or fter Week 24 (two consecutive vlues). b CVW t Wk 24: Prticipnts screening HIV-1-RNA ws 1,934,3 c/ml; their Dy 1 virl lod ws missing but their Dy 14 virl lod ws 14,867 c/ml nd their virl lod ws still declining through Wk 29. Dooley et l. CROI 218; Boston, MA. Conference on Retroviruses nd Opportunistic Infections; Mrch 4-7, 218; Boston, MA
9 Prticipnt with Confirmed Virologic Withdrwl 7 5-yer-old mle rndomized to DTG NRTI bckground regimen: ddi/3tc Screening HIV-1-RNA ws 1,934,3 c/ml (Dy 1 virl lod missing) HIV-1 RNA, log 1 c/ml No tretment-emergent NRTI, NNRTI, or INSTI resistnce observed Dy -27 Screening Dy 14 [18-Apr-16] Week 4 Week 8 Week 12 Week 24 [2-Sep-16] Week 24 Retest [6-Oct-216] Week 29 Dooley et l. CROI 218; Boston, MA. Conference on Retroviruses nd Opportunistic Infections; Mrch 4-7, 218; Boston, MA
10 Percentge, % Virologic nd Immunologic Results in the ITT-E Popultion Through Week Modified FDA snpshot nlysis (ITT-E) Proportion of Prticipnts With HIV-1 RNA <5 copies/ml, % (95% CI) Week DTG (n=69) EFV (n=44) 89 (79, 98) 81 (72, 9) INSPIRING Phrmcokinetic Dt Pre-dose concentrtion: DTG 5 mg BID with RIF Time n DTG Conc (ng/ml) Geomen (9%CI) %CV Wk (28-234) 118 Wk (19-338) 276 Pre-dose concentrtion: DTG 5 mg QD without RIF (post-tb tretment phse) Time n DTG Conc (ng/ml) Geomen (9%CI) %CV Wk (8-437) 151 Wk (19-331) 359 INSPIRING DTG C tu when dministered twice dily with RIF were similr to DTG 5 mg once dily without RIF nd to previously reported dt for DTG 5 mg once dily in Phse 2/3 HIV trils. Medin chnge from Bseline CD4+ cell count (Q1, Q3) t Week 24: DTG, 146 cells/mm 3 (71, 214); EFV 93 cells/mm 3 (47, 178) Dooley et l. CROI 218; Boston, MA. Conference on Retroviruses nd Opportunistic Infections; Mrch 4-7, 218; Boston, MA
11 Adverse Events At Time of Week 24 Dt Cut-off Dte n (%) DTG (n=69) EFV (n=44) Any AE 5 (72) 4 (91) AEs occurring in 1% of prticipnts in either group Hedche Upper respirtory trct infection Dirrhe Vomiting Dizziness Arthrlgi Gstroenteritis Any serious AE (SAE) Drug-relted SAEs Any drug-relted AE Grdes 1-2 Grde 3 Grde 4 9 (13) 5 (7) 2 (3) 5 (7) 3 (4) 8 (12) 1 (1) 4 (6) 1 (1) 17 (25) 15 (22) 2 (3) 5 (11) 7 (16) 8 (18) 5 (11) 6 (14) 5 (11) 5 (11) 1 (2) 13 (3) 12 (27) 1 (2) AEs leding to withdrwl 2 (5) b Any psychitric AE Grde 1-2 Grde 3-4 SAE 5 (7) 5 (7) 6 (14) 6 (14) 1 (2) c No ftl serious AEs in either group. b One prticipnt with EFV drug hypersensitivity nd one with γ-glutmyltrnsferse elevtion. c Grde 2 suicidl idetion, considered unrelted to study drug nd resolved the sme dy. Dooley et l. CROI 218; Boston, MA. Conference on Retroviruses nd Opportunistic Infections; Mrch 4-7, 218; Boston, MA
12 Prticipnts With TB nd Non TB-Associted IRIS n (%) Prticipnts with events sent to djudiction committee for TB-ssocited IRIS Met criteri for TB-ssocited IRIS Possibly met criteri for TB-ssocited IRIS Prticipnts with events sent to djudiction committee for non TB-ssocited IRIS Met criteri for non-tb-ssocited IRIS Possibly met criteri for non-tb-ssocited IRIS DTG (n=69) 9 (13) 4 (6) 2 (3) 1 c (1) 1 d (1) EFV (n=44) 12 (27) 4 b (9) 3 (7) No prticipnt in either rm permnently discontinued tretment due to IRIS 1 x Grde 1, 2 x Grde 2 nd 1 x Grde 3. b 3 x Grde 2 nd 1 x Grde 4. c Grde 2 (IRIS nd strongyloidisis; lso experienced TB-ssocited IRIS). d Grde 1 (Herpes zoster). Conference on Retroviruses nd Opportunistic Infections; Mrch 4-7, 218; Boston, MA Dooley et l. CROI 218; Boston, MA.
13 Prticipnts With Liver Chemistry Abnormlities Through Week 24 Dt Cut-off Dte Mximum post-bseline toxicity, n (%) DTG (n=69) EFV (n=44) ALT 3 ULN to <5 ULN 1 (2) ALT 5 ULN to <1 ULN 1 (1) 1 (2) ALT 1 ULN No subject discontinued study tretment due to liver chemistry bnormlities ALT, lnine minotrnsferse; ULN, upper limit of norml. Prticipnts were summrized on the bsis of mximum post-bseline vlue. Prticipnts with missing bseline dt were ssumed to be norml t bseline. Dooley et l. CROI 218; Boston, MA. Conference on Retroviruses nd Opportunistic Infections; Mrch 4-7, 218; Boston, MA
14 Conclusions DTG 5 mg BID during concomitnt RIF-bsed TB therpy demonstrted high efficcy nd good immunologicl response through Week 24 ITT-E popultion: 81% (95% CI: 72%, 9%) One prticipnt receiving DTG met CVW criteri nd no tretment-emergent resistnce-ssocited muttions detected Five (7%) of snpshot non-responders in the DTG group were due to discontinution for non-tretment-relted resons (minly lost to follow-up while suppressed) DTG C tu when dministered twice dily with RIF were similr to DTG 5 mg once dily without RIF nd to previously reported dt for DTG 5 mg once dily in Phse 2/3 HIV trils DTG ws well tolerted, the mjority of AEs were grde 1 or 2, with low rtes of drug-relted AEs nd serious AEs, nd no AEs leding to withdrwl Low rtes of TB- nd non TB-ssocited IRIS in both groups; none led to discontinution No AEs meeting the stopping criteri for drug-induced liver injury; none led to discontinution This study provides evidence tht DTG is effective nd well tolerted in dults with HIV/TB coinfection who re receiving RIF-bsed TB tretment Conference on Retroviruses nd Opportunistic Infections; Mrch 4-7, 218; Boston, MA Dooley et l. CROI 218; Boston, MA.
15 Prescribing Informtion Tivicy dolutegrvir 1mg, 25mg nd 5mg tblets See Summry of Product Chrcteristics before prescribing Indiction: HIV in >6 yers nd >15kg s prt of combintion therpy. Dosing: Adults & dolescents >4kg: 5mg once dily with or without food if no proven/ suspected integrse resistnce. Children 6 to <12 yers: dose ccording to bodyweight: 15-<2kg: 2mg once dily (2x1mg); 2-<3kg: 25mg once dily; 3-<4kg: 35mg once dily (1 x 25mg + 1 x 1mg); When codministered with efvirenz, nevirpine, tiprnvir/ritonvir, etrvirine (without boosted PI), crbmzepine, oxcrbzepine, phenytoin, phenobrbitl, St John s Wort or rifmpicin, Tivicy 5mg twice dily in dults/dolescents or the weight-bsed once dily dose twice dily in peditric ptients. Adults with proven/ suspected integrse resistnce: 5mg twice dily preferbly with food. Limited dt in peditric ptients with proven/suspected integrse resistnce. Elderly: Limited dt in 65+ yrs. Cution in severe heptic impirment. Contrindictions: Hypersensitivity to ny ingredient. Co-dministrtion with dofetilide. Wrnings/precutions: Risk of hypersensitivity rections. Discontinue dolutegrvir nd other suspect gents immeditely if suspected. Risks of osteonecrosis, immune rectivtion syndrome. Monitor LFTs in Heptitis B/C co-infection nd ensure effective Heptitis B therpy. Cution with metformin: monitor renl function nd consider metformin dose djustment. Use with etrvirine requires boosted PI or incresed dose of dolutegrvir. Use with Mg/Al-contining ntcids, clcium, multivitmins or iron requires dosge seprtion. Pregnncy/ lcttion: Not recommended. Avoid brest-feeding. Side effects: See SmPC for full detils. Hedche, GI disturbnce, insomni, bnorml drems, depression, nxiety, dizziness, rsh, pruritus, ftigue, elevtions of ALT, AST nd CPK, rthrlgi, mylgi, hypersensitivity, suicidl idetion or suicide ttempt. Bsic NHS costs: for 3 x 5mg tblets EU/1/13/892/ for 3 x 1mg tblets (EU/1/13/892/3) for 3 x 25mg tblets (EU/1/13/892/5). MA holder: ViiV Helthcre UK Ltd, 98 Gret West Rod, Brentford, Middlesex TW8 9GS. Further informtion vilble from Customer Contct Centre, GlxoSmithKline UK Ltd, Stockley Prk West, Uxbridge, Middlesex UB11 1BT. POM S1A Trde mrks re owned by or licensed to the ViiV Helthcre group of compnies. Dte of pprovl: Mrch 218. Zinc code: UK/DLG/55/13(12) Adverse events should be reported. For the UK, reporting forms nd informtion cn be found t or serch for MHRA Yellowcrd in the Google Ply or Apple App store. Adverse events should lso be reported to GlxoSmithKline on Adverse events should be reported. For Irelnd, dverse events should be reported directly to the HPRA; Freepost, Phrmcovigilnce Section, Helth Products Regultory Authority, Erlsfort Terrce, Dublin 2, Tel: , medsfety@hpr.ie. Adverse events should lso be reported to GlxoSmithKline on
The RUTHERFORD-2 trial in heterozygous FH: Results and implications
The RUTHERFORD-2 tril in heterozygous FH: Results nd implictions Slide deck kindly supplied s n eductionl resource by Professor Derick Rl MD PhD Crbohydrte & Lipid Metbolism Reserch Unit University of
More informationCheckMate 153: Randomized Results of Continuous vs 1-Year Fixed-Duration Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer
CheckMte 53: Rndomized Results of Continuous vs -Yer Fixed-Durtion Nivolumb in Ptients With Advnced Non-Smll Cell Lung Cncer Abstrct 297O Spigel DR, McCleod M, Hussein MA, Wterhouse DM, Einhorn L, Horn
More informationSafety and Tolerability of Subcutaneous Sarilumab and Intravenous Tocilizumab in Patients With RA
Sfety nd Tolerbility of Subcutneous Srilumb nd Intrvenous Tocilizumb in Ptients With RA Pul Emery, 1 Jun Rondon, 2 Anju Grg, 3 Hubert vn Hoogstrten, 3 Neil M.H. Grhm, 4 Ming Liu, 4 Nncy Liu, 3 Jnie Prrino,
More informationClinical Study Report Synopsis Drug Substance Naloxegol Study Code D3820C00018 Edition Number 1 Date 01 February 2013 EudraCT Number
EudrCT Number 2012-001531-31 A Phse I, Rndomised, Open-lbel, 3-wy Cross-over Study in Helthy Volunteers to Demonstrte the Bioequivlence of the Nloxegol 25 mg Commercil nd Phse III Formultions nd to Assess
More informationStart ORKAMBI today. INDICATIONS AND USAGE IMPORTANT SAFETY INFORMATION. Sydney Age 4
F O R H E A L T H C A R E P R O F E S S I O N A L S For ptients ge 2 yers nd older who re homozygous for the F508del muttion 1,2 Modify the course. Strt tody. Sydney Age 4 F508del/F508del INDICATIONS AND
More informationFLAMINGO 96-WEEK PRESENTATION DATA
FLAMINGO 96-WEEK PRESENTATION DATA Efficacy and safety of dolutegravir (DTG) in treatment-naïve subjects UK/DLG/0083/14j(4) Date of preparation: August 2017 Prescribing information is available at the
More informationIvy Song, 1 Kimberly Adkison, 2 Mark Lovern 3, Joannellyn Chiu 3, Jenny Huang 1, Cindy Vavro 1, Mounir Ait-Khaled 1, Brian Wynne 1 and Sherene Min 1
Pharmacokinetic-Pharmacodynamic Modeling & Simulation of the Virologic Response of Dolutegravir in HIV-Infected Patients with Integrase Inhibitor Resistant Virus Ivy Song, 1 Kimberly Adkison, 2 Mark Lovern
More informationSYNOPSIS Final Abbreviated Clinical Study Report for Study CA ABBREVIATED REPORT
Finl Arevited Clinicl Study Report Nme of Sponsor/Compny: Bristol-Myers Squi Ipilimum Individul Study Tle Referring to the Dossier (For Ntionl Authority Use Only) Nme of Finished Product: Yervoy Nme of
More informationGlaxoSmithKline, London, United Kingdom; 11 ViiV Healthcare, London, United Kingdom
Switching to Dolutegravir /Abacavir/Lamivudine Fixed Dose Combination ( FDC) from a PI, INI or NNRTI Based Regimen Maintains HIV Suppression at 48 Weeks J Lake, 1 B Trottier, 2 J Garcia-Diaz, 3 H Edelstein,
More informationVIKING STUDIES. Efficacy and safety of dolutegravir. treatment-experienced subjects
VIKING STUDIES Efficacy and safety of dolutegravir treatment-experienced subjects (DTG) in UK/DLG/0083/14e(2) Date of preparation: February 2017 Prescribing information is available at the end of this
More informationEfficacy of Pembrolizumab in Patients With Advanced Melanoma With Stable Brain Metastases at Baseline: A Pooled Retrospective Analysis
Efficcy of Pembrolizumb in Ptients With Advnced Melnom With Stble Brin Metstses t Bseline: A Pooled Retrospective Anlysis Abstrct 1248PD Hmid O, Ribs A, Dud A, Butler MO, Crlino MS, Hwu WJ, Long GV, Ancell
More informationFLAMINGO 96-WEEK PRESENTATION DATA
FLAMINGO 96-WEEK PRESENTATION DATA Efficacy and safety of dolutegravir (DTG) in treatment-naïve subjects UK/DLG/0083/14j(3) Date of preparation: February 2017 Prescribing information is available at the
More informationEfficacy of Sonidegib in Patients With Metastatic BCC (mbcc)
AAD 216 eposter 3368 Efficcy of Sonidegib in Ptients With Metsttic BCC (mbcc) Colin Morton, 1 Michel Migden, 2 Tingting Yi, 3 Mnish Mone, 3 Dlil Sellmi, 3 Reinhrd Dummer 4 1 Stirling Community Hospitl,
More informationPNEUMOVAX 23 is recommended by the CDC for all your appropriate adult patients at increased risk for pneumococcal disease 1,2 :
PNEUMOVAX 23 is recommended y the CDC for ll your pproprite dult ptients t incresed risk for pneumococcl disese 1,2 : Adults ged
More informationSINGLE STUDY DATA UP TO 144 WEEKS
SINGLE STUDY DATA UP TO 144 WEEKS Efficacy and safety of dolutegravir (DTG) in treatment-naïve subjects UK/DLG/0083/14a(3) Date of preparation: August 2017 Prescribing information is available at the end
More informationShort-term therapy with lasting relief 2
# 1 PRESCRIBED MEDICATION APPROVED FOR IBS-D 1 * Short-term therpy with lsting relief 2 provided up to 6 months of symptom relief with 2-week tretment 2 Rnge of 6 to 24 weeks; medin of 10 weeks. Convenient
More information58 % 50 % REDUCTION IN RISK OF OVERT HE RECURRENCE 1
FOR ADULT PATIENTS WITH OVERT HEPATIC ENCEPHALOPATHY (HE) significntly reduced the risk of overt HE recurrence nd HE-relted hospitliztions 1 58 % 50 % REDUCTION IN RISK OF OVERT HE RECURRENCE 1 REDUCTION
More informationAbstract. Background. Aim. Patients and Methods. Patients. Study Design
Impct of the Use of Drugs nd Substitution Tretments on the Antivirl Tretment of Chronic Heptitis C: Anlysis of Complince, Virologicl Response nd Qulity of Life (CHEOBS). Melin, 1 J.-. Lng, D. Ouzn, 3 M.
More informationIntroduction. These patients benefit less from conventional chemotherapy than patients identified as MMR proficient or microsatellite stable 3-5
Nivolumb + Ipilimumb Combintion in Ptients With DNA Mismtch Repir-Deficient/Microstellite Instbility-High Metsttic Colorectl Cncer: First Report of the Full Cohort From CheckMte-142 Abstrct 553 André T,
More informationAddendum to the Evidence Review Group Report on Aripiprazole for the treatment of schizophrenia in adolescents (aged years)
Addendum to the Evidence Review Group Report on Aripiprzole for the tretment of schizophreni in dolescents (ged 15-17 yers) Produced by Authors Correspondence to Southmpton Helth Technology Assessments
More informationSupplementary Online Content
Supplementry Online Content Zulmn DM, Pl Chee C, Ezeji-Okoye SC, et l. Effect of n intensive outptient progrm to ugment primry cre for high-need Veterns Affirs ptients: rndomized clinicl tril. JAMA Intern
More informationTarget: 10 mg/day within several days Schizophrenia in adolescents (2.1)
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include ll the informtion needed to use ZYPREXA sfely nd effectively. See full prescribing informtion for ZYPREXA. ZYPREXA (olnzpine) Tblet
More informationSeasonal influenza vaccination programme country profile: Ireland
Sesonl influenz vccintion progrmme country profile: Irelnd 2012 13 Seson Bckground informtion Influenz immunistion policy nd generl fcts bout Irelnd Volume indices of GDP per cpit in 2011 nd 2013 (EU-
More informationSINGLE STUDY DATA UP TO 144 WEEKS
SINGLE STUDY DATA UP TO 144 WEEKS Efficacy and safety of dolutegravir (DTG) in treatment-naïve subjects UK/DLG/0083/14a(2) Date of preparation: February 2017 Prescribing information is available at the
More informationAntiviral Therapy 2015; 20: (doi: /IMP2920)
Antivirl Therpy 2015; 20:397 405 (doi: 10.3851/IMP2920) Originl rticle Sfety, tolerbility nd phrmcokinetics of dorvirine, novel HIV non-nucleoside reverse trnscriptse inhibitor, fter single nd multiple
More informationTRIUMEQ * (DTG/ABC/3TC): BIOEQUIVALENCE DATA
TRIUMEQ * (DTG/ABC/3TC): BIOEQUIVALENCE DATA *In studies supporting TRIUMEQ, DTG 50 mg + ABC 600 mg/3tc 300 mg were used. Bioequivalence has been demonstrated. DTG, dolutegravir; ABC, abacavir; 3TC, lamivudine
More informationXALKORI (crizotinib) Is Available Through Specialty Pharmacies
XALKORI (crizotinib) Is Avilble Through Specilty Phrmcies Specilty Phrmcy Ordering Process The Provider s Office Submits XALKORI prescriptions to the specilty phrmcy vi: Phone Fx Internet Submits ny supporting
More informationPresented at the 75 th Annual Meeting of the American Academy of Dermatology, Orlando, FL, March 3-7, 2017 METHODS INTRODUCTION OBJECTIVE
Seven-Yer Interim Results from the ESPRIT 10-Yer Postmrketing Surveillnce Registry of Adlimumb for Moderte to Severe Psorisis Frncisco Kerdel, 1 Aln Menter, 2 Jshin J. Wu, 3 Mreike Bereswill, 4 Dilek Arikn,
More informationSafety of Ocrelizumab in Multiple Sclerosis: Updated Analysis in Patients With Relapsing and Primary Progressive Multiple Sclerosis
Sfety of Ocrelizumb in Multiple Sclerosis: Updted Anlysis in Ptients With Relpsing nd Primry Progressive Multiple Sclerosis SL Huser, L Kppos, X Montlbn, H Koendgen, C Chognot, C Li, C Mrcillt, A Prdhn,
More informationSponsor / Company: Sanofi Drug substance(s): AVE0005 (aflibercept)
These results re supplied for informtionl purposes only. Prescribing decisions should be mde bsed on the pproved pckge insert in the country of prescription. Sponsor / Compny: Snofi Drug substnce(s): AVE0005
More informationGemmis Injection 38 mg/ml
Gemmis Injection 8 mg/ml Gemcitbine (Gemcitbine HCl) is nucleoside nlogue tht exhibits nti-tumor ctivity. The empiricl formul for Gemcitbine HCl is C 9H 11F 2N O.HCl. It hs moleculr weight of 299.66. Gemcitbine
More informationSee 17 for PATIENT COUNSELING INFORMATION. Revised: 02/2011 FULL PRESCRIBING INFORMATION: CONTENTS*
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include ll the informtion needed to use GEMZAR sfely nd effectively. See full prescribing informtion for GEMZAR. GEMZAR (gemcitbine for injection)
More informationSee 17 for PATIENT COUNSELING INFORMATION and FDAapproved patient labeling. Revised: 6/2016 FULL PRESCRIBING INFORMATION: CONTENTS*
1 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include ll the informtion needed to use BASAGLAR sfely nd effectively. See full prescribing informtion for BASAGLAR BASAGLAR (insulin glrgine
More informationResults. Table 1: Demographic and Baseline Characteristics, Open-Label Safety Population Prior Double-Blind OC/APAP ER (n=77)
Open-Lbel Extension of Rndomized, Double-Blind, Plcebo-Controlled, Phse 3 Study of the Sfety nd Anlgesic Efficcy of MNK-795 Oxycodone/Acetminophen Extended-Relese (OC/APAP ER) Tblets in n Acute Pin Model
More informationT max (hr) 1.5 ± ± ± 0.6 AUC (0-10) (ng hr/ml)
Progesterone Cpsules (progesterone, USP), 100 mg nd 200 mg WARNING: CARDIOVASCULAR DISORDERS, BREAST CANCER nd PROBABLE DEMENTIA FOR ESTROGEN PLUS PROGESTIN THERAPY Crdiovsculr Disorders nd Probble Dementi
More informationAntiviral Therapy 2014; 19: (doi: /IMP2721)
Antivirl Therpy 2014; 19:191 200 (doi: 10.3851/IMP2721) Originl rticle Chnge in vitmin D levels nd risk of severe vitmin D deficiency over 48 weeks mong HIV 1 infected, tretment-nive dults receiving rilpivirine
More informationVIKING STUDIES Efficacy and safety of dolutegravir in treatment-experienced subjects
VIKING STUDIES Efficacy and safety of dolutegravir in treatment-experienced subjects IL/DLG/0040/14 June 2014 GSK (Israel) Ltd. Basel 25, Petach Tikva. Tel-03-9297100 Medical information service: il.medinfo@gsk.com
More information2.3. with type 1 diabetes <3 years of age. (8.4)
1 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include ll the informtion needed to use HUMALOG sfely nd effectively. See full prescribing informtion for HUMALOG. HUMALOG (insulin lispro
More informationA cross-sectional and follow-up study of leukopenia in tuberculosis patients: prevalence, risk factors and impact of anti-tuberculosis
Originl Article A cross-sectionl nd follow-up study of leukopeni in tuberculosis ptients: prevlence, risk fctors nd impct of nti-tuberculosis tretment Fei-Shen Lin 1 *, Mei-Ying Wu 2 *, Wen-Jun Tu 3, Hong-Qiu
More informationULTOMIRIS is administered once every 8 weeks a
(rvulizumb-cwvz) for the tretment of dult ptients with proxysml nocturnl hemoglobinuri (PNH) is dministered once every 8 weeks PATIENTS STARTING WITH NO PRIOR TREATMENT FOR PNH THE RECOMMENDED DOSING REGIMEN
More informationXII. HIV/AIDS. Knowledge about HIV Transmission and Misconceptions about HIV
XII. HIV/AIDS Knowledge bout HIV Trnsmission nd Misconceptions bout HIV One of the most importnt prerequisites for reducing the rte of HIV infection is ccurte knowledge of how HIV is trnsmitted nd strtegies
More informationIf Eligible, Get EFFEXOR XR Co-Pay Card Savings on Your Branded Prescription*
If Eligible, Get EFFEXOR XR Co-Py Crd Svings on Your Brnded Prescription* REMEMBER: You must be prescribed brnd-nme EFFEXOR XR to receive the monthly svings tht come with your Co-Py Crd. *Terms nd conditions
More informationImmune-Mediated Adverse Reactions Management Guide
Immune-Medited Adverse Rections Mngement Guide INDICATIONS AND USAGE YERVOY (ipilimumb) is indicted for: Tretment of unresectble or metsttic melnom in dults nd peditric ptients (12 yers nd older) Adjuvnt
More informationThe Hepatitis C treatment landscape is changing in Pakistan
The Heptitis C tretment lndscpe is chnging in Pkistn 01 A new dwn hs emerged in ccess to HCV Cure Ferozsons is herlding the chnge in the Heptitis C lndscpe of Pkistn In prtnership with Giled Sciences,
More informationSee 17 for PATIENT COUNSELING INFORMATION and Medication Guide. Revised: 10/2017
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include ll the informtion needed to use sfely nd effectively. See full prescribing informtion for. (ipilimumb) injection, for intrvenous use
More informationLê MP, 1,2 Cournil A, 3 Kouanfack C, 4 Lem S, 5 Le Gac S, 5 Delaporte E, 3 Peytavin G, 1,2 for the NAMSAL study group
Lê MP, 1,2 Cournil A, 3 Kouanfack C, 4 Lem S, 5 Le Gac S, 5 Delaporte E, 3 Peytavin G, 1,2 for the NAMSAL study group 1 AP-HP, Hopital Bichat, Pharmacology-Toxicology, Paris, France, 2 IAME, UMR 1137,
More informationA review of the patterns of docetaxel use for hormone-resistant prostate cancer at the Princess Margaret Hospital
MEDICAL ONCOLOGY A review of the ptterns of docetxel use for hormone-resistnt prostte cncer t the Princess Mrgret Hospitl S.N. Chin MD,* L. Wng MSc, M. Moore MD,* nd S.S. Sridhr MD MSc* ABSTRACT Bckground
More informationYERVOY (ipilimumab) injection, for intravenous use Initial U.S. Approval: 2011
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include ll the informtion needed to use sfely nd effectively. See full prescribing informtion for. (ipilimumb) injection, for intrvenous use
More informationAdverse Events Grading Card
Adverse Events Grding Crd Common Terminology Criteri for Adverse Events* In clinicl studies, 2 of the most common dverse events reported with ALAVEN were peripherl neuropthy nd neutropeni. 1 With this
More informationINVEGA SUSTENNA (paliperidone palmitate) extended-release injectable
(pliperidone plmitte) extended-relese injectble suspension, for intrmusculr use HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include ll the informtion needed to use sfely nd effectively.
More informationMEDALIST Trial Background and Rationale
The MEDALIST Tril: Results of Phse 3, Rndomized, Double-Blind, Plcebo-Controlled Study of to Tret Ptients With Very Low-, Low-, or Intermedite-Risk Myelodysplstic Syndromes (MDS) Associted Anemi With Ring
More informationWeight-Based Dosage Regimen: (2.1) Body Weight Range (kg) Loading Dose (mg) Maintenance Dose (mg) greater or equal to 40 to less than 60 2,400 3,000
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include ll the informtion needed to use sfely nd effectively. See full prescribing informtion for. (rvulizumb-cwvz) injection, for intrvenous
More informationSee 17 for PATIENT COUNSELING INFORMATION. Revised: 01/2018 FULL PRESCRIBING INFORMATION: CONTENTS*
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include ll the informtion needed to use sfely nd effectively. See full prescriing informtion for. (rifximin) tlets, for orl use Initil U.S.
More informationSee 17 for PATIENT COUNSELING INFORMATION. Revised: 09/2017 FULL PRESCRIBING INFORMATION: CONTENTS*
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include ll the informtion needed to use Gemzr sfely nd effectively. See full prescriing informtion for Gemzr. GEMZAR (gemcitine for injection),
More informationAntiviral Therapy 2015; 20: (doi: /IMP2874)
Antivirl Therpy 25; 2:79 79 (doi:.385/imp2874) Originl rticle Single dose permivir for the tretment of cute sesonl influenz: integrted nlysis of efficcy nd sfety from two plcebo-controlled trils Richrd
More informationSINGLE. Efficacy and safety of dolutegravir (DTG) in treatment-naïve subjects
SINGLE Efficacy and safety of dolutegravir (DTG) in treatment-naïve subjects SE/HIV/0023/14 January 2014 PHASE III DTG TRIALS IN TREATMENT-NAÏVE ADULT SUBJECTS WITH HIV SINGLE 1 N=833 Phase III non-inferiority,
More informationRecommended Dosage Regimen for AVYCAZ (ceftazidime and avibactam) b. AVYCAZ 1.25 grams (ceftazidime 1 gram and avibactam 0.25 grams) every 8 hours
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include ll the informtion needed to use AVYCAZ sfely nd effectively. See full prescribing informtion for AVYCAZ. AVYCAZ (ceftzidime nd vibctm)
More informationPatient Monitoring Checklist
Ptient Monitoring Checklist Ptient nme Dte This checklist is intended for nurses or other helthcre professionls (HCPs) to use prior to dosing ech ptient nd t ny follow-up visits or clls with the ptient
More informationIntroduction. Cahn et al. Andean Pacific HIV Clinical Forum 2017; Santiago, Chile. Abstract 2.
Efficacy of Dolutegravir/Abacavir/Lamivudine (DTG/ABC/3TC) Fixed Dose Combination (FDC) Compared With Ritonavir- Boosted Atazanavir (ATV/r) Plus Tenofovir Disoproxil Fumarate/Emtricitabine (TDF/FTC) in
More informationINVEGA SUSTENNA (paliperidone palmitate) extended-release injectable
(pliperidone plmitte) extended-relese injectble suspension, for intrmusculr use HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include ll the informtion needed to use sfely nd effectively.
More informationWARNING: RISK OF THYROID C CELL TUMORS
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include ll the informtion needed to use VICTOZA sfely nd effectively. See full prescriing informtion for VICTOZA. VICTOZA (lirglutide) injection,
More informationAssessment of Depression in Multiple Sclerosis. Validity of Including Somatic Items on the Beck Depression Inventory II
Assessment of Depression in Multiple Sclerosis Vlidity of Including Somtic Items on the Beck Depression Inventory II Peggy Crwford, PhD; Noh J. Webster, MA Signs nd symptoms of multiple sclerosis (MS)
More informationDOSAGE FORMS AND STRENGTHS HIGHLIGHTS OF PRESCRIBING INFORMATION
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include ll the informtion needed to use ALIMTA sfely nd effectively. See full prescribing informtion for ALIMTA. ALIMTA (pemetrexed disodium)
More informationManagement and Outcomes of Binge-Eating Disorder in Adults: Current State of the Evidence
Clinicin Summry Mentl Helth Eting Disorders Mngement nd Outcomes of Binge-Eting Disorder in Adults: Current Stte of the Evidence Focus of This Summry This is summry of systemtic review evluting the evidence
More informationPROVEN ANTICOCCIDIAL IN NEW FORMULATION
PROVEN ANTICOCCIDIAL IN NEW FORMULATION Coxidin 100 microgrnulte A coccidiosttic dditive for roilers, chickens rered for lying nd turkeys Contins 100 g of monensin sodium per kg Aville s homogenous grnules
More informationFor Adults With Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC)
For Adults With Previously Treted Advnced Non-Smll Cell Lung Cncer (NSCLC) individuls depicted re models used for illustrtive purposes only. It cn be overwhelming to lern tht your previously treted dvnced
More informationTHE CHB TREATMENT GUIDELINE NAVIGATOR REVIEW AN ONLINE INTERACTIVE GUIDE FOR CLINICIANS FEATURING EXPERT AUDIO COMMENTARY
The Americn Assocition for the Study of Liver Diseses () nd the Europen Assocition for the Study of Liver Disese () provide clinicl prctice guidelines for the mngement nd tretment of chronic heptitis B
More informationBudesonide Multimatrix Is Efficacious for Mesalamine-refractory, Mild to Moderate Ulcerative Colitis: A Randomised, Placebo-controlled Trial
Journl of Crohn's nd Colitis, 2017, 785 791 doi:10.1093/ecco-jcc/jjx032 Advnce Access publiction Mrch 4, 2017 Originl Article Originl Article Budesonide Multimtrix Is Efficcious for Meslmine-refrctory,
More informationThe Integrase Inhibitor Drug Class: A Comparative Clinical Review
The Integrase Inhibitor Drug Class: A Comparative Clinical Review Ian Frank Professor of Medicine University of Pennsylvania Philadelphia, PA USA franki@pennmedicine.upenn.edu Disclosure Gilead, ViiV/GlaxoSmithKline:
More informationProduct Monograph. Published by
Product Monogrph Pulished y INDICATION AND LIMITATION OF USE JARDIANCE is indicted s n djunct to diet nd exercise to improve glycemic control in dults with type 2 dietes mellitus. JARDIANCE is not recommended
More informationFULL PRESCRIBING INFORMATION
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include ll the informtion needed to use Herceptin sfely nd effectively. See full prescriing informtion for Herceptin. HERCEPTIN (trstuzum)
More informationCommunity. Profile Big Horn County. Public Health and Safety Division
Community Helth Profile 2015 Big Horn County Public Helth nd Sfety Division Tble of Contents Demogrphic Informtion 1 Communicble Disese 3 Chronic Disese 4 Mternl nd Child Helth 10 Mortlity 12 Behviorl
More informationUniversity of Texas Health Science Center, San Antonio, San Antonio, Texas, USA
Lung Cncer Chemotherpy Given Ner the End of Life by Community Oncologists for Advnced Non-Smll Cell Lung Cncer Jose R. Murillo, Jr., Jim Koeller b,c Methodist Hospitl, Houston, Texs, USA; b University
More informationCommunity. Profile Powell County. Public Health and Safety Division
Community Helth Profile 2015 Powell County Public Helth nd Sfety Division Tble of Contents Demogrphic Informtion 1 Communicble Disese 3 Chronic Disese 4 Mternl nd Child Helth 10 Mortlity 12 Behviorl Risk
More information10-15 mg/day 15 mg/day 30 mg/day. 2-5 mg/day 5-10 mg/day 15 mg/day. 2 mg/day 5-10 mg/day 15 mg/day. 30 mg/day injected IM
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include ll the informtion needed to use ABILIFY sfely nd effectively. See full prescribing informtion for ABILIFY. Tblets ABILIFY DISCMELT
More informationHERCEPTIN (trastuzumab) Intravenous Infusion Initial U.S. Approval: 1998
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include ll the informtion needed to use sfely nd effectively. See full prescriing informtion for. HERCEPTIN (trstuzum) Intrvenous Infusion
More informationA Randomized Phase III Clinical Trial of Plecanatide, a Uroguanylin Analog, in Patients With Chronic Idiopathic Constipation
ORIGINAL CONTRIBUTIONS 3 see relted editoril on pge x A Rndomized Phse III Clinicl Tril of Plecntide, Urogunylin Anlog, in Ptients With Chronic Idiopthic Constiption Philip B. Miner Jr, MD, Willim D. Koltun,
More informationIMPORTANT Reminders for Patients. IMPORTANT Information for Doctors/Nurses
Monitor Your Signs nd Symptoms (nivolum) is prescription medicine used in comintion with YERVOY (ipilimum) to tret type of skin cncer clled melnom tht hs spred or cnnot e removed y surgery (dvnced melnom).
More informationEmerging Options for Thromboprophylaxis After Orthopedic Surgery: A Review of Clinical Data
Emerging Options for Thromboprophylxis After Orthopedic Surgery: A Review of Clinicl Dt Bob L. Lobo, Phrm.D. In four rndomized, controlled studies of ptients undergoing orthopedic surgery, the ntithrombotic
More informationOriginal Article. Diabetes Metab J 2011;35:26-33 doi: /dmj pissn eissn
Originl Article Dibetes Metb J 211;35:26-33 doi: 1.493/dmj.211.35.1.26 pissn 2233-679 eissn 2233-687 D I A B E T E S & M E T A B O L I S M J O U R N A L Comprison of the Efficcy of Glimepiride, Metformin,
More informationA Comparison of Serum Magnesium Level in Pregnant Women with and without Gestational Diabetes Mellitus (GDM)
Brief Report J Bbol Univ Med Sci Vol 18, Issu 12; Dec 2016. P:71-75 A Comprison of Serum Mgnesium Level in Pregnnt Women with nd without Gesttionl Dibetes Mellitus (GDM) Z. Bouzri (MD) 1, F. Elmi(MD) 2,
More informationInvasive Pneumococcal Disease Quarterly Report. July September 2017
Invsive Pneumococcl Disese Qurterly Report July September 2017 Prepred s prt of Ministry of Helth contrct for scientific services by Rebekh Roos Helen Heffernn October 2017 Acknowledgements This report
More informationSee 17 for PATIENT COUNSELING INFORMATION and FDAapproved
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include ll the informtion needed to use ALIMTA sfely nd effectively. See full prescribing informtion for ALIMTA. ALIMTA (pemetrexed for injection),
More informationCommunity. Profile Yellowstone County. Public Health and Safety Division
Community Helth Profile 2015 Yellowstone County Public Helth nd Sfety Division Tble of Contents Demogrphic Informtion 1 Communicble Disese 3 Chronic Disese 4 Mternl nd Child Helth 10 Mortlity 12 Behviorl
More informationCommunity. Profile Lewis & Clark County. Public Health and Safety Division
Community Helth Profile 2015 Lewis & Clrk County Public Helth nd Sfety Division Tble of Contents Demogrphic Informtion 1 Communicble Disese 3 Chronic Disese 4 Mternl nd Child Helth 10 Mortlity 12 Behviorl
More informationCommunity. Profile Missoula County. Public Health and Safety Division
Community Helth Profile 2015 Missoul County Public Helth nd Sfety Division Tble of Contents Demogrphic Informtion 1 Communicble Disese 3 Chronic Disese 4 Mternl nd Child Helth 10 Mortlity 12 Behviorl Risk
More informationDiscuss IBS-D with your doctor
Discuss IBS-D with your doctor Mke sure to tlk out your IBS-D symptoms with your doctor it s n essentil step in deciding on the tretment pln tht s est for your needs. You cn use this converstion guide
More informationCommunity. Profile Anaconda- Deer Lodge County. Public Health and Safety Division
Community Helth Profile 2015 Ancond- Deer Lodge County Public Helth nd Sfety Division Tble of Contents Demogrphic Informtion 1 Communicble Disese 3 Chronic Disese 4 Mternl nd Child Helth 10 Mortlity 12
More informationSee 17 for PATIENT COUNSELING INFORMATION and FDAapproved. Revised: 01/2019
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include ll the informtion needed to use ALIMTA sfely nd effectively. See full prescribing informtion for ALIMTA. ALIMTA (pemetrexed for injection),
More informationRecall Bias in Childhood Atopic Diseases Among Adults in The Odense Adolescence Cohort Study
Syddnsk Universitet Recll Bis in Childhood Atopic Diseses Among Adults in The Odense Adolescence Cohort Study Mørtz, Chrlotte G; Andersen, Klus Ejner; Bindslev-Jensen, Crsten Published in: Act Dermto-Venereologic
More informationLevofloxacin in the Treatment of Pneumonia Caused by Streptococcus pneumoniae, Including Multidrug-Resistant Strains
Levofloxcin in the Tretment of Pneumoni Cused by Streptococcus pneumonie, Including Multidrug-Resistnt Strins Review Jnet Peterson, PhD Ortho-McNeil Jnssen Scientific Affirs, LLC; Rritn, New Jersey, USA
More informationClinical Evidence for Second- and Third-Line Treatment Options in Advanced Non-Small Cell Lung Cancer
Clinicl Evidence for Second- nd Third-Line Tretment Options in Advnced Non-Smll Cell Lung Cncer Filippo de Mrinis, Frncesco Grossi b Thorcic Oncology Unit I, Deprtment of Lung Diseses, Sn Cmillo nd Forlnini
More informationPrescribing Information can be found at the end of the presentation
Switching to Dolutegravir /Abacavir/Lamivudine Fixed Dose Combination ( FDC) from a PI, INI or NNRTI Based Regimen Maintains HIV Suppression at 48 Weeks Prescribing Information can be found at the end
More informationPRODUCT MONOGRAPH. Levofloxacin Tablets. 250 mg, 500 mg and 750 mg Levofloxacin (anhydrous) as Levofloxacin Hemihydrate. Antibacterial Agent
PRODUCT MONOGRAPH Pr SANDOZ LEVOFLOXACIN Tblets 250 mg, 500 mg nd 750 mg (nhydrous) s Hemihydrte Antibcteril Agent Sndoz Cnd Inc. Dte of Revision: June 25, 2014 145 Jules-Léger Boucherville, QC, Cnd J4B
More informationProduct Monograph INDICATIONS AND USAGE IMPORTANT RISK INFORMATION WARNING: RISK OF MEDICATION ERRORS AND HEPATOTOXICITY
Product Monogrph INDICATIONS AND USAGE OFIRMEV (cetminophen) injection is indicted for the mngement of mild to moderte pin, mngement of moderte to severe pin with djunctive opioid nlgesics, nd reduction
More informationRevised: 6/2018 History of severe hypersensitivity reaction to pemetrexed. (4)
HIGHLIGHTS OF PRESCRIBING INFORMATION ------------------------ WARNINGS AND PRECAUTIONS ----------------------- These highlights do not include ll the informtion needed to use ALIMTA sfely nd effectively.
More informationExcessive sleepiness is a cardinal symptom of many sleep disorders,
SCIENTIFIC INVESTIGATIONS Evlution of the Sfety of Modfinil for Tretment of Excessive Sleepiness Thoms Roth, Ph.D. 1 ; Jonthn R.L. Schwrtz, M.D. 2 ; Mx Hirshkowitz, Ph.D. 3 ; Milton K. Ermn, M.D. 4 ; Jeffrey
More informationReference Slide Deck. Abstract 553 Abstract 554 Abstract 560
Clinicl Spotlight Immunotherpy Advnces for Colorectl Crcinom in 2018: Newly Relesed Dt From the Gstrointestinl Cncers Symposium in Sn Frncisco Reference Slide Deck Abstrct 553 Abstrct 554 Abstrct 560 Mismtch
More informationAll- Oral 12- Week Combina3on Treatment With Daclatasvir and Sofosbuvir in Pa3ents Infected With HCV Genotype 3: ALLY- 3 Phase 3 Study
All- Orl 12- Week Combin3on Tretment With Dcltsvir nd Sofosbuvir in P3ents Infected With HCV Genotype 3: ALLY- 3 Phse 3 Study Nelson DR, 1 Cooper JN, 2 Llezri JP, 3 Lwitz E, 4 Pockros P, 5 Freilich BF,
More information